Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Neoplasms 46Squamous Cell Carcinoma of Head and Neck 45Head and Neck Neoplasms 35Lung Neoplasms 34Uterine Cervical Neoplasms 27Neoplasm Metastasis 26Unspecified Adult Solid Tumor, Protocol Specific 24Stomach Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 21Pancreatic Neoplasms 19Colorectal Neoplasms 18Cholangiocarcinoma 17Carcinoma, Squamous Cell 17Esophageal Neoplasms 16Breast Neoplasms 15Mesothelioma, Malignant 14Melanoma 13Urinary Bladder Neoplasms 12Mesothelioma 11Fallopian Tube Neoplasms 11Carcinoma, Ovarian Epithelial 11Sarcoma 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Biliary Tract Neoplasms 9Carcinoma 8Triple Negative Breast Neoplasms 7Recurrence 7

Interventions

Cyclophosphamide 11ruxolitinib 10fludarabine phosphate 9Tacrolimus 7Filgrastim 7fludarabine 6Decitabine 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Busulfan 5navitoclax 4Sirolimus 4Etoposide 4Azacitidine 4Specimen Handling 3Methylprednisolone 3Methotrexate 3Melphalan 3Cyclosporine 3Antilymphocyte Serum 3venetoclax 2thymoglobulin 2durvalumab 2Vorinostat 2Thiotepa 2Sunitinib 2Stem Cell Transplantation 2Radiotherapy 2Prednisone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Primary Myelofibrosis × Cisplatin × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡